Table 3.

Multivariate analysis.

Variable	OS	LFS	GRFS
	HR [95% CI]	HR [95% CI]	HR [95% CI]
	p	p	p
Patient age (1year increase)	1.02 [1.01–1.04] 0.007	1.03 [1.01–1.04] 0.003	1.01 [0.99–1.02] 0.5
PTCY vs. ATLG	0.69 [0.35–1.36] 0.3	0.62 [0.32–1.19] 0.2	1.21 [0.66–2.23] 0.5
HLA Mismatch vs Match	1.17 [0.65–2.09] 0.6	1.17 [0.67–2.06] 0.6	0.95 [0.53–1.70] 0.9
Patient CMV serology pos vs neg	1.53 [0.81–2.89] 0.2	1.28 [0.71–2.33] 0.4	1.38 [0.78–2.44] 0.3
PBSC vs. BM	0.5 [0.27–0.91] 0.023	0.48 [0.27–0.87] 0.015	1.02 [0.40–2.58] 0.9

	CIR
	HR [95% CI]
	p
Donor age (1 year increase)	0.991 [0.9596–1.023] 0.580
PTCY vs ATLG	0.268 [0.0841–0.851] 0.026
Source [PBSC vs BM]	0.413 [0.1733–0.986] 0.046
TBI [12 Gy vs <12 Gy]	0.121 [0.0362–0.406] 0.00063
	NRM
	HR [95% CI]
	p
Patient age (1 yr increase)	1.021 [1.000–1.040] 0.046
PTCY vs ATLG	0.809 [0.321–2.040] 0.650
Source [PBSC vs BM]	0.685 [0.299–1.570] 0.370

Bold values indicate statistical significance p  <  0.05.

OS overall survival, LFS leukemia-free survival, GRFS GvHD and relapse-free survival, CIR cumulative incidence of relapse, NRM non-relapse mortality, ATLG anti-t-lymphocyte globulin, PTCy post- transplant cyclophosphamide, P/D patient/donor, CMV cytomegalo virus, BM bone marrow, PBSC peripheral blood stem cell, TBI total body irradiation.